Characteristics of samples
| Sample . | n = 497 . |
|---|---|
| Median age (range) | 66 (45-82) |
| Sex, male (%) | 191 (38%) |
| Type (%) | |
| Asymptomatic carrier | 10 (2%) |
| Smoldering | 36 (7%) |
| Chronic (favorable) | 13 (3%) |
| Chronic (unfavorable) | 48 (10%) |
| Lymphoma | 11 (2%) |
| Acute | 379 (76%) |
| Post-mogamulizumab administration (%) | |
| Yes | 178 (36%) |
| No | 319 (64%) |
| Median value of each data (range) | |
| P fraction/CD4+ T cells, % | 49.1 (0.4-97.8) |
| D fraction/CD4+ T cells, % | 3.1 (0-89.3) |
| N fraction/CD4+ T cells, % | 17.3 (0-98.9) |
| N fraction (/μL) | 82 (0-113 839) |
| N/P ratio | 0.37 (0-246) |
| WBC (/× 103μL) | 5.43 (0.04-175.6) |
| Lymphocytes, % | 19 (0.5-85.5) |
| Lymphocytes (/μL) | 944 (34-15 030) |
| Abnormal lymphocytes, % | 1.5 (0-95.3) |
| Abnormal lymphocytes (/μL) | 86 (0-165 942) |
| sIL-2R, U/mL | 1 785 (189-192 231) |
| LDH, U/L | 246 (121-4 174) |
| Sample . | n = 497 . |
|---|---|
| Median age (range) | 66 (45-82) |
| Sex, male (%) | 191 (38%) |
| Type (%) | |
| Asymptomatic carrier | 10 (2%) |
| Smoldering | 36 (7%) |
| Chronic (favorable) | 13 (3%) |
| Chronic (unfavorable) | 48 (10%) |
| Lymphoma | 11 (2%) |
| Acute | 379 (76%) |
| Post-mogamulizumab administration (%) | |
| Yes | 178 (36%) |
| No | 319 (64%) |
| Median value of each data (range) | |
| P fraction/CD4+ T cells, % | 49.1 (0.4-97.8) |
| D fraction/CD4+ T cells, % | 3.1 (0-89.3) |
| N fraction/CD4+ T cells, % | 17.3 (0-98.9) |
| N fraction (/μL) | 82 (0-113 839) |
| N/P ratio | 0.37 (0-246) |
| WBC (/× 103μL) | 5.43 (0.04-175.6) |
| Lymphocytes, % | 19 (0.5-85.5) |
| Lymphocytes (/μL) | 944 (34-15 030) |
| Abnormal lymphocytes, % | 1.5 (0-95.3) |
| Abnormal lymphocytes (/μL) | 86 (0-165 942) |
| sIL-2R, U/mL | 1 785 (189-192 231) |
| LDH, U/L | 246 (121-4 174) |